INDIANAPOLIS (AP) — Chuck Pagano stepped to the podium Monday, hugged his team owner, thanked his family for its support and wiped a tear from his eye.
He might, finally, turn out the lights in his office, too.
Nearly three months to the day after being diagnosed with leukemia, the Colts' first-year coach returned to a team eager to reunite with a boss healthy enough to go back to work.
"I told you my best day of my life was July 1, 1989," Pagano said, referring to his wedding date. "Today was No. 2. Getting to pull up, drive in, get out of my car, the key fob still worked. I was beginning to question whether it would or not. When I asked for Bruce to take over, I asked for him to kick some you-know-what and to do great. Damn Bruce, you had to go and win nine games? Tough act to follow. Tough act to follow. Best in the history of the NFL. That's what I have to come back to."
The comment turned tears into the laughter everyone expected on such a festive occasion.
For Pagano and the Colts, Monday morning was as precious as anyone could have imagined when Pagano took an indefinite leave to face the biggest opponent of his life, cancer.
In his absence, all the Colts was win nine of 12 games, make a historic turnaround and clinch a playoff spot all before Sunday's regular-season finale against Houston, which they pegged as the day they hoped to have Pagano back. If all goes well at practice this week, Pagano will be on the sideline for the first time since a Week 3 loss to Jacksonville.
Pagano endured three rounds of chemotherapy to put his cancer in remission.
That Pagano's return came less than 24 hours after Indy (10-5) locked up the No. 5 seed in the AFC and the day before Christmas seemed fitting, too.
"I know Chuck is ready for this challenge. In speaking to his doctor multiple times, I know that the time is right for him to grab the reins, get the head coaching cap on and begin the journey," owner Jim Irsay said. "It's been a miraculous story. It really is a book. It's a fairytale. It's a Hollywood script. It's all those things but it's real."
The reality is that he's returning to a vastly different team than the one he turned over to Arians, his long-time friend and first assistant coaching hire.
Back then, the Colts were 1-2 and most of the so-called experts had written them off as one of the league's worst teams. Now, they're ready to show the football world that they can be just as successful under Pagano as they were under Arians, who tied the NFL record for wins after a midseason coaching change.
Pagano also has changed.
The neatly-trimmed salt-and-pepper hair and trademark goatee that were missing in November have slowly returned, and the thinner man who appeared to be catching his breath during a postgame speech in early November, looked and sounded as good as ever Monday.
He repeatedly thanked fans for their prayers and letters, the organization and his family for their unwavering help and promised to provide comfort and support to other people who are facing similar fights. During one poignant moment that nearly brought out tears again, Pagano even recounted a letter sent to him by a 9-year-old child who suggested he suck on ice chips and strawberry Popsicles in the hospital and advised him to be nice to the nurses regardless of how he felt — and he never even paused.
"I feel great, my weight is back, my energy is back and again, it's just a blessing to be back here," Pagano said.
In the minds of Colts players and coaches, Pagano never really left.
He continually watched practice tape and game film on his computer, used phone calls and text messages to regularly communicate with players and occasionally delivered a pregame or postgame speech to his team.
"He texted me and called me so much, it was like he was standing there in my face every day," said receiver Reggie Wayne, who has been friends with Pagano since the two were working together at the University of Miami.
But the Colts found plenty of other ways to keep Pagano's battle in the forefront.
They began a fundraising campaign for leukemia research, calling it Chuckstrong. Players had stickers with the initials CP on their locker room nameplates, and Arians wore an orange ribbon on his baseball cap during games. Orange is the symbolic color for leukemia. At one point, nearly three dozen players shaved their heads to show their ailing coach they were with him.
That's not all.
Arians and first-year general manager Ryan Grigson decided to leave the lights on in Pagano's office until he returned. Pagano noted the team even installed plastic clips to make sure those lights were not mistakenly turned off while he was gone. Those clips were removed when Pagano arrived Monday morning.
And Arians said nobody sat in the front seat of the team bus.
"He's always been our head coach," Arians said.
So after getting medical clearance from his oncologist, Dr. Larry Cripe, to return with no restrictions, Pagano couldn't wait to get to the office Monday morning.
Arians arrived at 7 a.m., three hours early for the scheduled team meeting. By then, Pagano had already driven past the inflatable Colts player with the words "Welcome Back Chuck" printed on its chest and was back in his office preparing for the Texans.
Players showed up a couple of hours later, and when the torch was passed from Arians back to Pagano, players gave their returning coach a standing ovation that Wayne said was well-deserved.
All Pagano wants to do now is emulate the success Arians and his players have had this season.
"I asked him (Arians) if he would lead this team and this ballclub and this organization and take over the reins," Pagano said. "What a masterful, masterful job you did Bruce. You carried the torch and all you went out and did was win nine ballgames. You got us our 10th win yesterday and you got us into the playoffs. You did it with dignity and you did it with class. You're everything that I always knew you were and more."
___
Online: http://pro32.ap.org/poll and http://twitter.com/AP_NFL
KABUL, Afghanistan — A woman identified as a police officer shot and killed an American civilian adviser at police headquarters in Kabul on Monday, Afghan police officials said, breaking a relative lull in the so-called insider killings that have strained the relationship between Americans and Afghans here.
Afghan policemen at the site where a female police officer reportedly shot and killed an American civilian adviser on Monday.
A spokesman for the American-led NATO force in Afghanistan, Col. Thomas W. Collins, confirmed that the attack had taken place but said that the victim’s name was being withheld according to military policy. He described the attacker as “a suspected member of the Afghan uniformed police” and said the suspect was in Afghan custody.
Insider attacks, in which members of the Afghan security services have turned against their foreign allies, have greatly increased in the past year, with 61 American and other coalition members killed, not including the episode on Monday, compared with 35 deaths the previous year, according to NATO figures.
Monday’s attack — the first insider attack known to be committed by a woman — came after a lull in insider shootings after the military instituted a series of precautions meant to reduce them. The most recent episode was on Nov. 11, when a British soldier was killed in Helmand Province.
A person at Kabul police headquarters, where the shooting occurred at about 10 a.m., said the suspect, a woman named Nargis, was a police officer who had been detached to work in the Interior Ministry’s legal and gender equality department. The person, who spoke on condition of anonymity because he was not authorized to release information, said the attacker had used a pistol and had shot the adviser, an engineer working in construction, in the head at close range.
He said the suspect had been arrested at the scene by Afghan police officers. Although the person did not specify a motive, he said that it was not related to terrorism and that the suspect had no known connections with insurgents.
American and Afghan officials have been struggling to figure out how large a factor Taliban infiltration or coercion has been in the increase in insider killings this year. Although insurgent contact has been clear in some cases, many of the attacks have seemed to come out of personal animosity or outrage, attributed to culture clash or growing Afghan anger at what they see as an unwelcome occupation by the United States and its allies.
In other violence on Monday, a coalition member was killed in an insurgent attack in eastern Afghanistan, and an Afghan Local Police commander killed five fellow officers at a checkpoint in Jowzjan Province in the north. Dur Mohammad, the commander at the checkpoint, shot and killed five officers under his command, according to Gen. Abdul Aziz Ghairat, the provincial police chief. He said the commander fled after the shooting. General Ghairat did not offer a motive but said that Mr. Mohammad had connections with the Taliban in the area.
The Afghan Local Police program, which seeks to bring armed elements — including some former insurgents — into government service, has drawn criticism because of a series of episodes in which the armed elements have switched allegiances, sometimes repeatedly.
As the use of personal technology increases at work, it’s important to observe some new etiquette rules about how we use it. Here are eight of the most important rules to follow at work when it comes to cell phones, email, and other modern technology.
1. Using speaker phone when others can hear you. Playing back your voicemail messages on speaker phone or conducting an entire call on speaker phone is distracting to people trying to work around you. Even if you’re in an office with the door closed, speakerphone noises tend to travel. Don’t value your hands-free convenience over the ability of others to focus on their work.
2. Keeping your cell phone out so you can glance at it during meetings. Glancing down at your phone while you’re supposed to be focused on a meeting signals that you’re bored, not fully engaged, or don’t respect the time of the people you’re meeting with. If you must keep your phone out because you’re expecting an important call or text, explain that at the start of the meeting so that people don’t assume you’re just being rude.
3. Don’t overuse “reply all.” When multiple people are included on an email chain, they don’t all need to see your reply of “thanks” or “will do.” Only use “reply all” if everyone included truly needs to see your response; otherwise, stick with “reply” so your response goes only to the sender and doesn’t clutter multiple in-boxes.
4. Don’t email and phone with the same message; pick one or the other. Nothing is more annoying than starting to read an email, only to have the email’s sender pop his head in your office to repeat the same message.
5. Turn off your cell phone’s ringer if you leave it behind while you’re away from your desk. Ask any office worker, and you’ll hear stories about the annoying guy who leaves his phone behind with his ringer on full-volume while he goes to meetings … leaving his co-workers forced to hear repeated renditions of “Who Let the Dogs Out” or whatever else he’s chosen for his ringtone.
6. Placing calls from a noisy location. If you make a call, ensure you’re somewhere where you and the person you’re speaking with will be able to hear each other–and where you can give your full focus. It’s irritating to get a call from someone who immediately puts you on hold to order coffee because she just reached the front of the line.
7. Keep religious and political messages out of your email signature. Including religious or political messages is likely to offend or at least irritate some of your recipients, and introduces topics that don’t belong in a professional setting. Keep your sign-off neutral and professional.
8. Don’t use your work email as your personal email. In most offices, sending occasional personal emails from your work account is fine, but you should use your personal account for most personal things. If you treat your work email as your default personal account, chances are good that when you leave your job and your inbox and sent folder are full of personal messages, one of your co-workers will be stuck reading through all of them, as they clean out your account for your replacement. In the best case scenario, that’s merely a nuisance for a co-worker –but in the worst case scenario, it could lead to embarrassing revelations.
Alison Green writes the popular Ask a Manager blog, where she dispenses advice on career, job search, and management issues. She’s also the co-author of Managing to Change the World: The Nonprofit Manager’s Guide to Getting Results, and former chief of staff of a successful nonprofit organization, where she oversaw day-to-day staff management, hiring, firing, and employee development.
Wireless News Headlines – Yahoo! News
SEATTLE (AP) — Red Bryant remembers the early years of his career, when the Seattle Seahawks struggled to win only four and five games in his first two seasons.
Getting a 10th win on Sunday night and a trip to the postseason was special to the Seahawks' big defensive end.
"Who has been playing better than us the last few weeks?" Bryant questioned. "This is the National Football League and you don't get any gimmies. We work hard to win. ... It's hard to win in this league."
Russell Wilson threw a career-high four touchdown passes to move into second place for most TD passes by a rookie, Marshawn Lynch scored two first-quarter TDs, and the Seahawks routed the San Francisco 49ers 42-13.
Richard Sherman returned Bryant's blocked field goal 90 yards for another touchdown as the Seahawks (10-5) jumped to a 21-0 lead. That only added to an already hyped crowd on a typically cold and rainy December night, with noise echoing off the walls and overhanging roof of CenturyLink Field that might have been heard all the way across Puget Sound.
No one appeared to care about the weather, not with the performance they were seeing on the field. And not with a ticket to the postseason guaranteed thanks to Seattle's first 10-win season since 2007.
"We knew we were capable of doing this. We had no doubt. Even in Week 1, we knew that we had the talent to do what we're doing now," said wide receiver Doug Baldwin, who had two touchdown receptions. "It took time because we're a young team. We had to mature. We had to grow together, build that chemistry, build that trust out there on the field. That's the most important thing."
Seattle surged into the playoffs on the strength of its sixth win in seven games, putting up dizzying offensive numbers that no one thought would continue against the top scoring defense in the NFL but did.
Seattle has outscored its last three opponents 150-30. The 42 points were the most allowed since Jim Harbaugh took over the 49ers, and the most San Francisco yielded since giving up 45 to Atlanta in 2009. It was the perfect way for Seattle coach Pete Carroll to snap a three-game losing streak against his rival.
"We just try to play really good football and see what happens at the end," Carroll said. "We have been scoring and doing a nice job of it and it would be great If we can keep it rolling."
Seattle will likely be the No. 5 seed in the NFC. There remains a slight chance of winning the NFC West, if the Seahawks beat St. Louis in the season finale and Arizona can upset the 49ers in San Francisco.
The Seahawks, 7-0 at home, delayed San Francisco (10-4-1) from celebrating a division title. They turned Harbaugh's 49th birthday into a miserable evening.
"If you had told me this would be the outcome I wouldn't have believed it," Sherman said. "I would say you're making this up."
Wilson hit Lynch on a 9-yard TD in the first quarter, Anthony McCoy for a 6-yarder late in the first half, and Doug Baldwin on 4 and 6 yard TDs in the second half.
Wilson has 25 TD passes, one behind Peyton Manning's NFL rookie record of 26. He finished 15 of 21 for 171 yards. His only incompletion in the first half was a deflected pass that Patrick Willis intercepted.
Wilson's counterpart, San Francisco's Colin Kaepernick, had already proven himself capable of winning on the road with victories in New Orleans and last week in New England. But Seattle is a different beast, widely regarded by players as the loudest venue in the NFL. His inexperience playing in such an environment showed. He was flustered and disorganized at the line of scrimmage, letting the noise from Seattle's fans affect him.
Kaepernick's forgettable night was capped when Sherman stepped in front of his pass intended for Randy Moss at the back of the end zone on the first play of the fourth quarter for his seventh interception of the season.
Kaepernick was 19 of 36 for 244 yards with an 18-yard TD pass to Delanie Walker with 1:40 left. Frank Gore had just 28 yards on six carries after rushing for a season-high 131 when the teams met in Week 7.
"Every time you are on the field you are learning something," Kaepernick said. "We just have to take what we can from this game and move on to next week."
San Francisco played without defensive tackle Justin Smith due to an elbow injury that ended a streak of 185 starts. The 49ers lost tight end Vernon Davis in the first quarter with a concussion sustained when he was knocked off his feet on a huge hit along the sideline from Seattle safety Kam Chancellor that looked legal but drew a penalty for hitting a defenseless receiver.
San Francisco wide receiver Mario Manningham went down with a left leg injury early in the third quarter when he was tackled low by Leroy Hill and fumbled.
The loss of Smith affected the entire defense. Aldon Smith was left stuck on 19 1-2 sacks after being locked up by Seattle offensive tackle Russell Okung.
"We can't make excuses," 49ers' safety Donte Whitner said. "We understand: We lost the football game; we lost an ugly football game."
NOTES: Lynch finished with 111 yards on 26 carries, his third straight game over 100 yards vs. the 49ers. ... Seattle was 11 of 13 on third-down conversions, a season-high. ... The 49ers were held to 82 yards rushing, just the third time this season he was held under 100 yards.
___
Online: http://pro32.ap.org/poll and http://twitter.com/AP_NFL
Training to become a doctor takes so long that just the time invested has become, to many, emblematic of the gravity and prestige of the profession.
But now one of the nation’s premier medical schools, New York University, and a few others around the United States are challenging that equation by offering a small percentage of students the chance to finish early, in three years instead of the traditional four.
Administrators at N.Y.U. say they can make the change without compromising quality, by eliminating redundancies in their science curriculum, getting students into clinical training more quickly and adding some extra class time in the summer.
Not only, they say, will those doctors be able to hang out their shingles to practice earlier, but they will save a quarter of the cost of medical school — $49,560 a year in tuition and fees at N.Y.U., and even more when room, board, books, supplies and other expenses are added in.
“We’re confident that our three-year students are going to get the same depth and core knowledge, that we’re not going to turn it into a trade school,” said Dr. Steven Abramson, vice dean for education, faculty and academic affairs at N.Y.U. School of Medicine.
At this point, the effort involves a small number of students at three medical schools: about 16 incoming students at N.Y.U., or about 10 percent of next year’s entering class; 9 at Texas Tech Health Science Center School of Medicine; and even fewer, for now, at Mercer University School of Medicine’s campus in Savannah, Ga. A similar trial at Louisiana State University has been delayed because of budget constraints.
But Dr. Steven Berk, the dean at Texas Tech, said that 10 or 15 other schools across the country had expressed interest in what his university was doing, and the deans of all three schools say that if the approach works, they will extend the option to larger numbers of students.
“You’re going to see this kind of three-year pathway become very prominent across the country,” Dr. Abramson predicted.
The deans say that getting students out the door more quickly will accomplish several goals. By speeding up production of physicians, they say, it could eventually dampen a looming doctor shortage, although the number of doctors would not increase unless the schools enrolled more students in the future.
The three-year program would also curtail student debt, which now averages $150,000 by graduation, and by doing so, persuade more students to go into shortage areas like pediatrics and internal medicine, rather than more lucrative specialties like dermatology.
The idea was supported by Dr. Ezekiel J. Emanuel, a former health adviser to President Obama, and a colleague, Victor R. Fuchs. In an editorial in the Journal of the American Medical Association in March, they said there was “substantial waste” in the nation’s medical education. “Years of training have been added without evidence that they enhance clinical skills or the quality of care,” they wrote. They suggested that the 14 years of college, medical school, residency and fellowship that it now takes to train a subspecialty physician could be reduced by 30 percent, to 10 years.
That opinion, however, is not universally held. Other experts say that a three-year medical program would deprive students of the time they need to delve deeply into their subjects, to consolidate their learning and to reach the level of maturity they need to begin practicing, while adding even more pressure to a stressful academic environment.
“The downside is that you are really tired,” said Dr. Dan Hunt, co-secretary of the Liaison Committee on Medical Education, the accrediting agency for medical schools in the United States and Canada. But because accreditation standards do not dictate the fine points of curriculum, the committee has approved N.Y.U.’s proposal, which exceeds by five weeks its requirement that schools provide at least 130 weeks of medical education.
The medical school is going ahead with its three-year program despite the damage from Hurricane Sandy, which forced NYU Langone Medical Center to evacuate more than 300 patients at the height of the storm and temporarily shut down three of its four main teaching hospitals.
Dr. Abramson of N.Y.U. said that postgraduate training, which typically includes three years in a hospital residency, and often fellowships after that, made it unnecessary to try to cram everything into the medical school years. Students in the three-year program will have to take eight weeks of class before entering medical school, and stay in the top half of their class academically. Those who do not meet the standards will revert to the four-year program.
TARTUS, Syria — Loyalists who support the government of President Bashar al-Assad are flocking to the Mediterranean port of Tartus, creating an overflowing boomtown far removed from the tangled, scorched rubble that now mars most Syrian cities.
The port city of Tartus is sheltered by a mountain range.
There are no shellings or air raids to interrupt the daily calm. Families pack the cafes lining the town’s seaside corniche, usually abandoned in December to the salty winter winds. The real estate market is brisk. A small Russian naval base provides at least the impression that salvation, if needed, is near.
Many of the new residents are members of the Alawite minority, the same Shiite Muslim sect to which Mr. Assad belongs. The latest influx is fleeing from Damascus, people who have decided that summer villas, however chilly, are preferable to the looming battle for the capital.
“Going to Tartus is like going to a different country,” said a Syrian journalist who recently met residents here. “It feels totally unaffected and safe. The attitude is, ‘We are enjoying our lives while our army is fighting overseas.’ ”
Should Damascus fall to the opposition, Tartus could become the heart of an attempt to create a different country. Some expect Mr. Assad and the security elite will try to survive the collapse by establishing a rump Alawite state along the coast, with Tartus as their new capital.
There have been various signs of preparations.
This month, the governor of Tartus Province announced that experts were studying how to develop a tiny local airfield, now used mostly by crop-dusters, into a full-fledged civilian airport “to boost transportation, business, travel and tourism,” as the official Syrian news agency, SANA, reported. The announcement coincided with the first attacks on the airport in Damascus, forcing it to close temporarily to international traffic.
More important, security forces are continuously tightening an extensive ring of checkpoints around the potential borders of an Alawite canton. The mountain heartland of the Alawites rises steeply to the east of Tartus, separating it from much of Syria. Across the mountains, the Orontes River creates a rough line separating Alawite territory from central Syria. Rebel military commanders from adjoining Hama Province said government soldiers vigorously maintain checkpoints on routes leading up into the mountains.
“If we bomb a checkpoint, it is back in place sometimes within hours,” said Basil al-Hamwi, a rebel fighter, speaking on the sidelines of a meeting of opposition military commanders in Turkey. “Once, in Hama Province, we destroyed five in one day and they were all back the next day. This area is even more important for them than Damascus.”
Mr. Hamwi and other rebel leaders said there were about 40 government checkpoints along more than 60 miles in Homs and Hama Provinces alone. Many Alawite commanders of Mr. Assad’s army have sent their families to their home villages, so they are particularly aggressive in protecting the area, said Hassan M. al-Saloom, a rebel battalion commander. They have formed committees to guard the outskirts of their villages, he said, and often negotiate local truces.
“Nobody goes inside, and they don’t come out,” he said.
There are widespread suspicions within the opposition that the military is shipping weapons into the Alawite hinterland, or has already positioned them. “The mountains and the coast make it hard to raid,” Mr. Saloom said.
Castles left by the Crusaders dot the coastal range, a testament to its strategic value.
If Mr. Assad fled to Tartus, he could seek protection from the Russian naval base here, or flee aboard a Russian vessel. Russia announced Tuesday that it was sending a small flotilla toward Tartus, possibly to evacuate its citizens who live in Syria. But Tartus residents said that the Russian families from the naval base had already left, while the officers do not leave the base, which is little more than an enclosure near the civilian port.
DETROIT (AP) — Matt Ryan got what he wanted.
Calvin Johnson was forced to settle for what he could get.
Ryan matched a career high with four touchdown passes, two to Roddy White, to help the Atlanta Falcons beat the Detroit Lions 31-18 Saturday night and earn home-field advantage throughout the NFC playoffs.
"It's great," Ryan said. "Our confidence is high and our experience — good and bad — has helped us. The key is to keep the focus where it's been."
In yet another loss, Johnson had a record-breaking night.
Johnson broke Jerry Rice's NFL single-season yards receiving mark of 1,848. After making the record-breaking catch in the fourth quarter, Johnson jogged over to the sideline and handed the football to his father.
"That was a very special moment," he said.
Johnson also became the only player with 100 yards receiving in eight straight games and the first with 10 receptions in four games in a row in league history. He had 11 receptions for 225 yards, giving him 1,892 this season.
"I've been an NFL fan my whole life, dating back to watching Johnny Unitas and Raymond Berry as a kid, and I've coached in this league for 19 years," Detroit coach Jim Schwartz said. "I've seen a lot of Hall of Famers, but I've never seen a better player than Calvin Johnson.
"He just broke a record set by Jerry Rice, who is arguably the best player in this history of this league."
The Falcons (13-2) pulled away with Ryan's fourth TD pass to wide-open tight end Michael Palmer in the fourth quarter and Matt Bryant's 20-yard field goal with 3:05 left that gave them a 15-point lead.
Ryan was 25 of 32 for 279 yards without a turnover.
The Falcons hope playing at home, potentially throughout the conference playoffs, helps them more than it did after the 2010 and 1980 seasons. The Falcons failed to win a game in either postseason, getting routed by Green Bay two years ago and blowing a double-digit, fourth-quarter lead to Dallas three decades ago.
Atlanta advanced to its only Super Bowl with a win at Minnesota after winning a franchise-record 14 games during the 1998 season.
The Falcons won't have much incentive to match that mark next week at home against Tampa Bay, when they'll have nothing to gain and something to lose if a key player or more gets hurt.
Detroit (4-11) has been relegated to playing for pride this month and that hasn't been going very well.
The Lions, whose seven-game losing streak is the longest skid in the league, haven't struggled this much since the laughingstock of a franchise became the league's first to go 0-16 in 2008.
The Falcons led 21-3 at halftime before letting the Lions pull within five points early in the fourth quarter.
Ryan dashed Detroit's comeback hopes.
Facing intense pressure, he converted a third down in Atlanta territory with a pass to White, picked on rookie cornerback Jonte Green by throwing to Jones to pick up more first downs and found Tony Gonzalez open to convert another third down to set up his fourth TD pass.
"We didn't play well in the third quarter," Atlanta coach Mike Smith said. "Matt made some big throws on that drive."
Stafford was clearly trying to get the ball to Johnson on the next drive and cornerback Asante Samuel figured that out, stepping in front of the receiver for an interception to set up Bryant's field goal.
Atlanta running back Michael Turner was tackled in the end zone, after Detroit turned the ball over on downs, to give the Lions two meaningless points.
Ryan went deep to White for the first score, connecting with him on a 44-yard TD strike with 5:50 left in the first quarter. Ryan threw a short pass to him early in the second quarter and the standout receiver did the rest on a 39-yard sprint down the sideline.
Ryan put his third TD pass where only Julio Jones could catch it a corner of the end zone, and he did on a 16-yard reception that put Atlanta up 21-3.
Detroit didn't give up, a game after being accused of doing just that in a 38-10 loss at Arizona.
Jason Hanson kicked a second field goal late in the first half to make it 21-6.
After Atlanta opened the second half with a three-and-out drive, Mikel Leshoure scored on a 1-yard run midway through the third quarter to pull the Lions with eight points.
Hanson's third field goal made it 21-16.
Stafford finished 37 of 56 for 443 yards with an interception and the Lions say he set an NFL record for the most yards passing in a game without throwing a TD pass.
Detroit dug a big hole because the Falcons scored two TDs off turnovers in the first half.
Defensive end Kroy Biermann forced running Leshoure to fumble, giving the Falcons the ball at their 31 and they took advantage. Ryan's perfectly lofted pass to White's fingertips converted a third-and-1 in a big way, putting the Falcons ahead.
The Lions responded with another drive into Atlanta territory, but stalled and had to settle for Hanson's 34-yard field goal in the final minute of the opening quarter to pull within four points.
Atlanta earned a double-digit lead on the ensuing drive.
Ryan threw a screen pass to his left to White, who got a great block from tight end Gonzalez, and the receiver raced untouched for a score that put the Falcons ahead 14-3.
White finished with eight receptions for 153 yards and two TDs. Jones had seven receptions for 71 yards and a score.
Ryan completed his first 12 attempts and, after his first incomplete pass, he converted a third-and-10 with an 11-yard toss to Jacquizz Rodgers. Two plays later, Ryan matched a season high with a third TD pass on the connection with Jones. Prior to the game, Ryan hadn't started a game with more than 10 consecutive completions, according to STATS LLC. He started 10 for 10 last month against Tampa Bay.
Johnson had three receptions for 70 yards in the first quarter, breaking Herman Moore's single-season franchise record for yards receiving.
By halftime, Johnson had 117 yards receiving. He had 100 yards receiving for an eighth straight game, breaking a record set by Charley Hennigan in 1961 and matched by Michael Irvin in 1995. It was Johnson's 11th game with 100 yards receiving this season, tying Irvin's NFL mark.
"Calvin is one of the best players in the game and I think everybody is a big fan of his," Ryan said. "He's one of the most genuinely nice people you could meet."
Stafford connected with Johnson on a short crossing route and the receiver did the rest, outrunning Falcons on a 49-yard gain. Fittingly, the Lions turned the ball over on the next snap in the latest lowlight in a season full of them.
The Lions, Falcons and fans at Ford Field in Detroit honored the victims of the shootings at Sandy Hook Elementary School before the game. Players had memorial decals on their helmets that read "S.H.E.S." in white on a black background, and Detroit's coaches wore pins with a similar design. There was also a moment of silence before the national anthem while the names and ages of each victim were shown on the videoboards. Twenty children and six adults were killed in the Dec. 14 shooting in Newtown, Conn. Adam Lanza killed his mother, shot students and staff, then killed himself.
NOTES: Stafford, in his fourth season, has 1,090 career completions to surpass Bobby Layne's franchise record of 1,074. Stafford is seven attempts away from surpassing the NFL's single-season mark of 691 set by Drew Bledsoe with New England in 1994. ... Backup Falcons CB Christopher Owens had a hamstring injury.
___
Online: http://pro32.ap.org/poll and http://twitter.com/AP_NFL
___
Follow Larry Lage on Twitter: http://twitter.com/larrylage
C.J. Gunther for The New York Times
Dr. Donald Bergstrom is a cancer specialist at Sanofi, one of three companies working on a drug to restore a tendency of damaged cells to self-destruct.
For the first time ever, three pharmaceutical companies are poised to test whether new drugs can work against a wide range of cancers independently of where they originated — breast, prostate, liver, lung. The drugs go after an aberration involving a cancer gene fundamental to tumor growth. Many scientists see this as the beginning of a new genetic age in cancer research.
Great uncertainties remain, but such drugs could mean new treatments for rare, neglected cancers, as well as common ones. Merck, Roche and Sanofi are racing to develop their own versions of a drug they hope will restore a mechanism that normally makes badly damaged cells self-destruct and could potentially be used against half of all cancers.
No pharmaceutical company has ever conducted a major clinical trial of a drug in patients who have many different kinds of cancer, researchers and federal regulators say. “This is a taste of the future in cancer drug development,” said Dr. Otis Webb Brawley, the chief medical and scientific officer of the American Cancer Society. “I expect the organ from which the cancer came from will be less important in the future and the molecular target more important,” he added.
And this has major implications for cancer philanthropy, experts say. Advocacy groups should shift from fund-raising for particular cancers to pushing for research aimed at many kinds of cancer at once, Dr. Brawley said. John Walter, the chief executive officer of the Leukemia and Lymphoma Society, concurred, saying that by pooling forces “our strength can be leveraged.”
At the heart of this search for new cancer drugs are patients like Joe Bellino, who was a post office clerk until his cancer made him too sick to work. Seven years ago, he went into the hospital for hernia surgery, only to learn he had liposarcoma, a rare cancer of fat cells. A large tumor was wrapped around a cord that connects the testicle to the abdomen. “I was shocked,” he said in an interview this summer.
Companies have long ignored liposarcoma, seeing no market for drugs to treat a cancer that strikes so few. But it is ideal for testing Sanofi’s drug because the tumors nearly always have the exact genetic problem the drug was meant to attack — a fusion of two large proteins. If the drug works, it should bring these raging cancers to a halt. Then Sanofi would test the drug on a broad range of cancers with a similar genetic alteration. But if the drug fails against liposarcoma, Sanofi will reluctantly admit defeat.
“For us, this is a go/no-go situation,” said Laurent Debussche, a Sanofi scientist who leads the company’s research on the drug.
The genetic alteration the drug targets has tantalized researchers for decades. Normal healthy cells have a mechanism that tells them to die if their DNA is too badly damaged to repair. Cancer cells have grotesquely damaged DNA, so ordinarily they would self-destruct. A protein known as p53 that Dr. Gary Gilliland of Merck calls the cell’s angel of death normally sets things in motion. But cancer cells disable p53, either directly, with a mutation, or indirectly, by attaching the p53 protein to another cellular protein that blocks it. The dream of cancer researchers has long been to reanimate p53 in cancer cells so they will die on their own.
The p53 story began in earnest about 20 years ago. Excitement ran so high that, in 1993, Science magazine anointed it Molecule of the Year and put it on the cover. An editorial held out the possibility of “a cure of a terrible killer in the not too distant future.”
Companies began chasing a drug to restore p53 in cells where it was disabled by mutations. But while scientists know how to block genes, they have not figured out how to add or restore them. Researchers tried gene therapy, adding good copies of the p53 gene to cancer cells. That did not work.
Then, instead of going after mutated p53 genes, they went after half of cancers that used the alternative route to disable p53, blocking it by attaching it to a protein known as MDM2. When the two proteins stick together, the p53 protein no longer functions. Maybe, researchers thought, they could find a molecule to wedge itself between the two proteins and pry them apart.
The problem was that both proteins are huge and cling tightly to each other. Drug molecules are typically tiny. How could they find one that could separate these two bruisers, like a referee at a boxing match?
In 1996, researchers at Roche noticed a small pocket between the behemoths where a tiny molecule might slip in and pry them apart. It took six years, but Roche found such a molecule and named it Nutlin because the lab was in Nutley, N.J.
But Nutlins did not work as drugs because they were not absorbed into the body.
Roche, Merck and Sanofi persevered, testing thousands of molecules.
At Sanofi, the stubborn scientist leading the way, Dr. Debussche, maintained an obsession with p53 for two decades. Finally, in 2009, his team, together with Shaomeng Wang at the University of Michigan and a biotech company, Ascenta Therapeutics, found a promising compound.
The company tested the drug by pumping it each day into the stomachs of mice with sarcoma.
C.J. Gunther for The New York Times
Dr. Donald Bergstrom is a cancer specialist at Sanofi, one of three companies working on a drug to restore a tendency of damaged cells to self-destruct.
For the first time ever, three pharmaceutical companies are poised to test whether new drugs can work against a wide range of cancers independently of where they originated — breast, prostate, liver, lung. The drugs go after an aberration involving a cancer gene fundamental to tumor growth. Many scientists see this as the beginning of a new genetic age in cancer research.
Great uncertainties remain, but such drugs could mean new treatments for rare, neglected cancers, as well as common ones. Merck, Roche and Sanofi are racing to develop their own versions of a drug they hope will restore a mechanism that normally makes badly damaged cells self-destruct and could potentially be used against half of all cancers.
No pharmaceutical company has ever conducted a major clinical trial of a drug in patients who have many different kinds of cancer, researchers and federal regulators say. “This is a taste of the future in cancer drug development,” said Dr. Otis Webb Brawley, the chief medical and scientific officer of the American Cancer Society. “I expect the organ from which the cancer came from will be less important in the future and the molecular target more important,” he added.
And this has major implications for cancer philanthropy, experts say. Advocacy groups should shift from fund-raising for particular cancers to pushing for research aimed at many kinds of cancer at once, Dr. Brawley said. John Walter, the chief executive officer of the Leukemia and Lymphoma Society, concurred, saying that by pooling forces “our strength can be leveraged.”
At the heart of this search for new cancer drugs are patients like Joe Bellino, who was a post office clerk until his cancer made him too sick to work. Seven years ago, he went into the hospital for hernia surgery, only to learn he had liposarcoma, a rare cancer of fat cells. A large tumor was wrapped around a cord that connects the testicle to the abdomen. “I was shocked,” he said in an interview this summer.
Companies have long ignored liposarcoma, seeing no market for drugs to treat a cancer that strikes so few. But it is ideal for testing Sanofi’s drug because the tumors nearly always have the exact genetic problem the drug was meant to attack — a fusion of two large proteins. If the drug works, it should bring these raging cancers to a halt. Then Sanofi would test the drug on a broad range of cancers with a similar genetic alteration. But if the drug fails against liposarcoma, Sanofi will reluctantly admit defeat.
“For us, this is a go/no-go situation,” said Laurent Debussche, a Sanofi scientist who leads the company’s research on the drug.
The genetic alteration the drug targets has tantalized researchers for decades. Normal healthy cells have a mechanism that tells them to die if their DNA is too badly damaged to repair. Cancer cells have grotesquely damaged DNA, so ordinarily they would self-destruct. A protein known as p53 that Dr. Gary Gilliland of Merck calls the cell’s angel of death normally sets things in motion. But cancer cells disable p53, either directly, with a mutation, or indirectly, by attaching the p53 protein to another cellular protein that blocks it. The dream of cancer researchers has long been to reanimate p53 in cancer cells so they will die on their own.
The p53 story began in earnest about 20 years ago. Excitement ran so high that, in 1993, Science magazine anointed it Molecule of the Year and put it on the cover. An editorial held out the possibility of “a cure of a terrible killer in the not too distant future.”
Companies began chasing a drug to restore p53 in cells where it was disabled by mutations. But while scientists know how to block genes, they have not figured out how to add or restore them. Researchers tried gene therapy, adding good copies of the p53 gene to cancer cells. That did not work.
Then, instead of going after mutated p53 genes, they went after half of cancers that used the alternative route to disable p53, blocking it by attaching it to a protein known as MDM2. When the two proteins stick together, the p53 protein no longer functions. Maybe, researchers thought, they could find a molecule to wedge itself between the two proteins and pry them apart.
The problem was that both proteins are huge and cling tightly to each other. Drug molecules are typically tiny. How could they find one that could separate these two bruisers, like a referee at a boxing match?
In 1996, researchers at Roche noticed a small pocket between the behemoths where a tiny molecule might slip in and pry them apart. It took six years, but Roche found such a molecule and named it Nutlin because the lab was in Nutley, N.J.
But Nutlins did not work as drugs because they were not absorbed into the body.
Roche, Merck and Sanofi persevered, testing thousands of molecules.
At Sanofi, the stubborn scientist leading the way, Dr. Debussche, maintained an obsession with p53 for two decades. Finally, in 2009, his team, together with Shaomeng Wang at the University of Michigan and a biotech company, Ascenta Therapeutics, found a promising compound.
The company tested the drug by pumping it each day into the stomachs of mice with sarcoma.
Copyright © access News. All rights reserved.
Design 
And Business Directories
